Efferocytosis and Respiratory Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Oct 14

PMID 37834319

Authors

Wenxue Zheng

Zhengjie Zhou

Xiaoping Guo

Xu Zuo

Jiaqi Zhang

Yiming An

Haoyu Zheng

Yuan Yue

Guoqiang Wang

Fang Wang

Affiliations

Soon will be listed here.

Abstract

Cells are the smallest units that make up living organisms, which constantly undergo the processes of proliferation, differentiation, senescence and death. Dead cells need to be removed in time to maintain the homeostasis of the organism and keep it healthy. This process is called efferocytosis. If the process fails, this may cause different types of diseases. More and more evidence suggests that a faulty efferocytosis process is closely related to the pathological processes of respiratory diseases. In this review, we will first introduce the process and the related mechanisms of efferocytosis of the macrophage. Secondly, we will propose some methods that can regulate the function of efferocytosis at different stages of the process. Next, we will discuss the role of efferocytosis in different lung diseases and the related treatment approaches. Finally, we will summarize the drugs that have been applied in clinical practice that can act upon efferocytosis, in order to provide new ideas for the treatment of lung diseases.

Citing Articles

Alveolar-capillary endocytosis and trafficking in acute lung injury and acute respiratory distress syndrome.

Kryvenko V, Vadasz I Front Immunol. 2024; 15:1360370.

PMID: 38533500 PMC: 10963603. DOI: 10.3389/fimmu.2024.1360370.

References

Mehrotra P, Ravichandran K . Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discov. 2022; 21(8):601-620. PMC: 9157040. DOI: 10.1038/s41573-022-00470-y. View

Hussain N, Wu F, Zhu L, Thrall R, Kresch M . Neutrophil apoptosis during the development and resolution of oleic acid-induced acute lung injury in the rat. Am J Respir Cell Mol Biol. 1998; 19(6):867-74. DOI: 10.1165/ajrcmb.19.6.3118. View

Barkal A, Brewer R, Markovic M, Kowarsky M, Barkal S, Zaro B . CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572(7769):392-396. PMC: 6697206. DOI: 10.1038/s41586-019-1456-0. View

Kourtzelis I, Hajishengallis G, Chavakis T . Phagocytosis of Apoptotic Cells in Resolution of Inflammation. Front Immunol. 2020; 11:553. PMC: 7137555. DOI: 10.3389/fimmu.2020.00553. View

Rath M, Muller I, Kropf P, Closs E, Munder M . Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages. Front Immunol. 2014; 5:532. PMC: 4209874. DOI: 10.3389/fimmu.2014.00532. View

Gregoire M, Uhel F, Lesouhaitier M, Gacouin A, Guirriec M, Mourcin F . Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS. Eur Respir J. 2018; 52(2). DOI: 10.1183/13993003.02590-2017. View

Truman L, Ford C, Pasikowska M, Pound J, Wilkinson S, Dumitriu I . CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008; 112(13):5026-36. DOI: 10.1182/blood-2008-06-162404. View

Tsai R, Discher D . Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008; 180(5):989-1003. PMC: 2265407. DOI: 10.1083/jcb.200708043. View

Vandivier R, Fadok V, Hoffmann P, Bratton D, Penvari C, Brown K . Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest. 2002; 109(5):661-70. PMC: 150889. DOI: 10.1172/JCI13572. View

10.

Im S, Osborne T . Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011; 108(8):996-1001. PMC: 3082200. DOI: 10.1161/CIRCRESAHA.110.226878. View

11.

Calligaris M, Cuffaro D, Bonelli S, Spano D, Rossello A, Nuti E . Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution. Molecules. 2021; 26(4). PMC: 7916773. DOI: 10.3390/molecules26040944. View

12.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

13.

Doran A, Yurdagul Jr A, Tabas I . Efferocytosis in health and disease. Nat Rev Immunol. 2019; 20(4):254-267. PMC: 7667664. DOI: 10.1038/s41577-019-0240-6. View

14.

Felton J, Lucas C, Dorward D, Duffin R, Kipari T, Vermeren S . Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation. J Allergy Clin Immunol. 2018; 142(6):1884-1893.e6. PMC: 6281028. DOI: 10.1016/j.jaci.2018.01.029. View

15.

Mao Y . Apoptotic cell-derived metabolites in efferocytosis-mediated resolution of inflammation. Cytokine Growth Factor Rev. 2021; 62:42-53. DOI: 10.1016/j.cytogfr.2021.10.002. View

16.

Nepal S, Tiruppathi C, Tsukasaki Y, Farahany J, Mittal M, Rehman J . STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation. Proc Natl Acad Sci U S A. 2019; 116(33):16513-16518. PMC: 6697797. DOI: 10.1073/pnas.1821601116. View

17.

Morimoto K, Janssen W, Fessler M, McPhillips K, Borges V, Bowler R . Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006; 176(12):7657-65. DOI: 10.4049/jimmunol.176.12.7657. View

18.

Salina A, Dos-Santos D, Rodrigues T, Fortes-Rocha M, Freitas-Filho E, Alzamora-Terrel D . Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells. Elife. 2022; 11. PMC: 9262386. DOI: 10.7554/eLife.74443. View

19.

Park S, Jung M, Kim H, Lee S, Kim S, Lee B . Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 2007; 15(1):192-201. DOI: 10.1038/sj.cdd.4402242. View

20.

GILES K, Ross K, Rossi A, Hotchin N, Haslett C, Dransfield I . Glucocorticoid augmentation of macrophage capacity for phagocytosis of apoptotic cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high levels of active Rac. J Immunol. 2001; 167(2):976-86. DOI: 10.4049/jimmunol.167.2.976. View